AstraZeneca PLC (NASDAQ:AZN)
| 65.98 Delayed Data As of Jan 26 |  -0.64 / -0.96%Today’s Change | 52.65 Today|||52-Week Range 72.12 | -2.68% Year-to-Date |
Five Year Financial Summary
| All Currency in US Dollars | 4 Year Trend | |||||
|---|---|---|---|---|---|---|
2015 | 2016 | 2017 | 2018 | |||
| Operating Activities | Net Income / Starting Line | 3.1B | 3.5B | 2.3B | 2.0B | |
| Depreciation | 2.7B | 2.3B | 2.5B | 2.8B | ||
| Total Other Cash Flow | -2.2B | -2.5B | -897.5M | -1.3B | ||
| Funds From Operations | 3.5B | 3.4B | 3.8B | 3.4B | ||
| Funds From/For Other Operating Expenses | 48.9M | -923.6M | 50.5M | 637.9M | ||
| Net Cash Flow - Operating Activities | 3.4B | 4.3B | 3.8B | 2.8B | ||
| Investing | Increase In Investments | -101.8M | -435.9M | -522.5M | -288.5M | |
| Decrease In Investments | 375.4M | 3.0M | 70.8M | 428.3M | ||
| Capital Expenditures | -1.3B | -1.4B | -1.3B | -1.0B | ||
| Fixed Asset Disposal | 46.9M | 81.8M | 83.9M | 12.0M | ||
| Net Assets From Acquisitions | -3.0B | -2.9B | -1.9B | -348.4M | ||
| Other Investing - Sources | 1.1B | 1.4B | 1.4B | 2.3B | ||
| Net Cash Flow Investing | -4.4B | -4.1B | -2.5B | 768.7M | ||
| Financing | Short Term Borrowings | -1.5B | -302.2M | 339.6M | -97.8M | |
| Long Term Borrowings | 5.9B | 2.5B | 0.00 | 0.00 | ||
| Long Term Debt Reduction | -41.9M | -16.0M | -14.2M | 0.00 | ||
| Net Proceeds Stock Sale | 42.9M | 46.9M | 43.5M | 33.9M | ||
| Common Preferred Redeemed | 0.00 | 0.00 | 0.00 | 0.00 | -- | |
| Common Dividends | -3.5B | -3.6B | -3.6B | -3.5B | ||
| Cash Dividends Paid - Total | -3.5B | -3.6B | -3.6B | -3.5B | ||
| Other Sources - Financing | -- | 18.0M | 0.00 | 0.00 | ||
| Other Uses - Financing | 50.9M | 0.00 | 20.2M | 66.9M | ||
| Net Cash Flow - Financing | 876.6M | -1.3B | -3.0B | -2.0B | ||
| Exchange Rate | Effect of Exchange Rate on Cash | -75.9M | 20.9M | -66.7M | -37.9M | |
| Net Change In Cash | -36.9M | -1.1B | -1.7B | 1.5B | ||